1. Scrip
  2. >>Business
  3. >>Deals

HAYA To Complement Lilly’s Metabolic Disease Efforts With Long Non-Coding RNA

 
• By Joseph Haas

HAYA, a pioneer in lncRNA, is teaming up with Lilly to discover novel targets and programmable RNA therapies for obesity and metabolic disorders.

Dark genome
HAYA is partnering with Lilly on dark genome-derived therapies • Source: Shutterstock

Long non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company, already a leader in obesity and metabolic disease, is partnering with the Swiss biotech HAYA Therapeutics, SA in a multiyear discovery collaboration to find new therapeutic targets and preclinical candidates within the “dark genome.”

Key Takeaways

  • Focused on the dark genome and long non-coding RNA therapeutics, HAYA is partnering with Lilly to discover novel targets to address obesity and metabolic disease.

The two firms announced their collaboration, with an estimated total value of up to $1bn for HAYA, on 4 September....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

More from Business

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.